Cost Effectiveness Analysis Osseo-Integrated Protheses for Transfemoral Amputation

Research Objectives Evaluate US costs and effectiveness using a disease state specific quality of life instrument for treatment naïve and refractory patients transfemoral amputees using a socket and osseointegrated prosthesis. Design Lifetime Markov models. Setting Home. Participants Treatment refractory and treatment naïve healthy and active middle-aged male transfemoral amputees evaluated for costs and quality of life assessment over their lifetime. Interventions Evaluation of cost and quality of life for socket and osseointegrated prosthesis in a decision tree Markov model. Main Outcome Measures Lifetime cost of direct medical care; lifetime quality of life as measured by Q-TFA (quality of life transfemoral amputee). Results For treatment naïve patients and treatment refractory the ICERs were as follows over various timeframes (Table 1): Table 1: Incremental cost effectiveness analysis In sensitivity analysis, related to variable thresholds that would affect a change in the course of treatment based on cost alone the following were found to do so in the treatment naïve group: Yearly replacement components of >$7,857 (socket) and; Initial cost of OPRA prosthesis $14,407. Conclusions The use of the OPRA prostheses provides a cost-effective alternative to a socket prosthesis when evaluated with a disease specific health instrument. The use of the OPRA prosthesis should be considered both in treatment naïve and treatment refractory socket prosthesis patients. Author(s) Disclosures JV is a cost effectiveness expert working with Integrum. Evaluate US costs and effectiveness using a disease state specific quality of life instrument for treatment naïve and refractory patients transfemoral amputees using a socket and osseointegrated prosthesis. Lifetime Markov models. Home. Treatment refractory and treatment naïve healthy and active middle-aged male transfemoral amputees evaluated for costs and quality of life assessment over their lifetime. Evaluation of cost and quality of life for socket and osseointegrated prosthesis in a decision tree Markov model. Lifetime cost of direct medical care; lifetime quality of life as measured by Q-TFA (quality of life transfemoral amputee). For treatment naïve patients and treatment refractory the ICERs were as follows over various timeframes (Table 1): Table 1: Incremental cost effectiveness analysis In sensitivity analysis, related to variable thresholds that would affect a change in the course of treatment based on cost alone the following were found to do so in the treatment naïve group: Yearly replacement components of >$7,857 (socket) and; Initial cost of OPRA prosthesis $14,407. The use of the OPRA prostheses provides a cost-effective alternative to a socket prosthesis when evaluated with a disease specific health instrument. The use of the OPRA prosthesis should be considered both in treatment naïve and treatment refractory socket prosthesis patients.